Abstract:ABSTRACT The recently discovered Middle East respiratory syndrome coronavirus (MERS-CoV) continues to infect humans, with high mortality. Specific, highly effective therapeutics and vaccines against the MERS-CoV are urgently needed to save human lives and address the pandemic concerns. We identified three human monoclonal antibodies (MAbs), m336, m337, and m338, targeting the receptor (CD26/DPP4) binding domain (RBD) of the MERS-CoV spike glycoprotein from a very large naïve-antibody library (containing ∼1011 antibodies). They bound with high affinity: equilibrium dissociation constants for the three MAbs were equal to 4.2, 9.3, and 15 nM, respectively, as measured by Biacore for Fabs binding to RBD. The avidity for IgG1 m336, m337, and m338 was even higher: 99, 820, and 560 pM, respectively. The antibodies bound to overlapping epitopes that overlap the receptor binding site on the RBD as suggested by competition experiments and further supported by site-directed mutagenesis of the RBD and a docking model of the m336-RBD complex. The highest-affinity MAb, m336, neutralized both pseudotyped and live MERS-CoV with exceptional potency, 50% neutralization at 0.005 and 0.07 μg/ml, respectively, likely by competing with DPP4 for binding to the S glycoprotein. The exceptionally high neutralization activity of these antibodies and especially m336 suggests that they have great potential for prophylaxis and therapy of MERS-CoV infection in humans and as a tool for development of vaccine immunogens. The rapid identification (within several weeks) of potent MAbs suggests a possibility to use the new large antibody library and related methodology for a quick response to the public threat resulting from emerging coronaviruses. IMPORTANCE A novel human coronavirus, the Middle East respiratory syndrome coronavirus (MERS-CoV), was found to infect humans with a high mortality rate in 2012, just 1 decade after the appearance of the first highly pathogenic coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV). There are no effective therapeutics available. It is highly desirable to find an approach for rapidly developing potent therapeutics against MERS-CoV, which not only can be implemented for MERS treatment but also can help to develop a platform strategy to combat future emerging coronaviruses. We report here the identification of human monoclonal antibodies (MAbs) from a large nonimmune antibody library that target MERS-CoV. One of the antibodies, m336, neutralized the virus with exceptional potency. It therefore may have great potential as a candidate therapeutic and as a reagent to facilitate the development of vaccines against MERS-CoV.

Exceptionally Potent Neutralization of Middle East Respiratory Syndrome Coronavirus by Human Monoclonal Antibodies

Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From A Recovered Patient

Potent Neutralization of MERS-CoV by Human Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein.

Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein to Avoid Neutralization Escape

Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection.

A Humanized Neutralizing Antibody Against Mers-Cov Targeting the Receptor-Binding Domain of the Spike Protein

Characterization of a Human Monoclonal Antibody Generated from a B-cell Specific for a Prefusion-Stabilized Spike Protein of Middle East Respiratory Syndrome Coronavirus.

A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein

Towards a Solution to MERS: Protective Human Monoclonal Antibodies Targeting Different Domains and Functions of the MERS-coronavirus Spike Glycoprotein

Identification of Human Neutralizing Antibodies Against Mers-Cov and Their Role in Virus Adaptive Evolution

A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein.

A MERS-CoV Antibody Neutralizes a Pre-Emerging Group 2c Bat Coronavirus

Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset

Development of Human Neutralizing Monoclonal Antibodies for Prevention and Therapy of MERS-CoV Infections

Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection

Antibodies And Vaccines Against Middle East Respiratory Syndrome Coronavirus

Human Monoclonal Antibody Cocktail for the Treatment or Prophylaxis of Middle East Respiratory Syndrome Coronavirus

A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (Mers-Cov) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy Against MERS-CoV

Research progress on human neutralizing monoclonal antibodies against Middle East respiratory syndrome coronavirus

Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV.

Combining A Fusion Inhibitory Peptide Targeting The Mers-Cov S2 Protein Hr1 Domain And A Neutralizing Antibody Specific For The S1 Protein Receptor-Binding Domain (Rbd) Showed Potent Synergism Against Pseudotyped Mers-Cov With Or Without Mutations In Rbd